<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717688</url>
  </required_header>
  <id_info>
    <org_study_id>NEP and GLP-1</org_study_id>
    <nct_id>NCT03717688</nct_id>
  </id_info>
  <brief_title>The Effects of Neprilysin on Glucagon-like Peptide-1</brief_title>
  <acronym>NEP</acronym>
  <official_title>The Effects of Neprilysin on Glucagon-like Peptide-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolai Jacob Wewer Albrechtsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of
      a neprilysin inhibitor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced
      insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within
      minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A
      few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the
      degradation of GLP-1 but if this is the case in humans is unknown. We therefore administered
      a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and
      100mg 2 hours before), both, or place, to nine healthy men during a standardized meal and
      measured plasma concentrations of GLP-1
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">May 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The participants are on 4 study days with wash out period of minimum 2 weeks randomized to 4 intervention arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GLP-1</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
    <description>changes in plasma GLP-1 using immunological methods: intact and total GLP-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
    <description>changes in C-peptide using immunological methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
    <description>Changes in Plasma glucagon concentrations using different analytical methodologies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood glucose</measure>
    <time_frame>3 hours after treatment and during the subsequent standardized meal</time_frame>
    <description>changes in blood glucose using immunological methods</description>
  </other_outcome>
  <other_outcome>
    <measure>GIP</measure>
    <time_frame>3 hours after treatment ( during the subsequent standardized meal)</time_frame>
    <description>changes in plasma GIP using immunological methods</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetes</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No treatment. Participants are subjected to a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entrestro as single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin as single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entrestro + sitagliptin as single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entresto</intervention_name>
    <description>Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan</description>
    <arm_group_label>Entrestro + sitagliptin as single dose</arm_group_label>
    <arm_group_label>Entrestro as single dose</arm_group_label>
    <other_name>ARNI</other_name>
    <other_name>Neprilysin inhibibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <description>2 x 100mg sitagliptin as single dose.</description>
    <arm_group_label>Entrestro + sitagliptin as single dose</arm_group_label>
    <arm_group_label>Sitagliptin as single dose</arm_group_label>
    <other_name>DPP-4 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>No treatment</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men

          -  body mass index between 20-25

        Exclusion Criteria:

          -  acute diseases within the two weeks

          -  chronic diseases

          -  smoker

          -  alcoholism, drug addiction or recent weight loss

          -  blood donation within the last 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Wewer Albrechtsen NJ, Mark PD, Terzic D, Hansen LH, Andersen UÃ˜, Hartmann B, Carr RD, Gustafsson F, Deacon CF, Holst JJ, Goetze JP, Plomgaard P. Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men. J Clin Endocrinol Metab. 2019 May 10. pii: jc.2019-00515. doi: 10.1210/jc.2019-00515. [Epub ahead of print]</citation>
    <PMID>31074791</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Nicolai Jacob Wewer Albrechtsen</investigator_full_name>
    <investigator_title>Junior Consultant</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Neprilysin</keyword>
  <keyword>DPP-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

